Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine

被引:7
作者
Bocket, L
Yazdanpanah, Y
Ajana, F
Gerard, Y
Viget, N
Goffard, A
Alcaraz, I
Wattré, P
Mouton, Y
机构
[1] Ctr Hosp Reg Univ, Serv Univ Virol, Lille, France
[2] Ctr Hosp Tourcoing, Serv Univ Malad Infect & Voyageur, Tourcoing, France
[3] Inst Pasteur, Ctr Immunol & Biol Parasitaire, CNRS, U362,Ctr Rech Econ Sociol & Gest, F-59019 Lille, France
关键词
HIV-1 drug resistance; antiretroviral therapy; zidovudine; stavudine;
D O I
10.1093/jac/dkh006
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Aims: The aims of this study were to: (i) determine the incidence of thymidine-associated mutations (TAMs) in an observational clinical cohort of naive HIV-1 patients who stopped first-line therapy including either zidovudine or stavudine; and (ii) assess the immunological and virological responses to subsequent second-line therapy in patients who switched from zidovudine to stavudine or conversely. Patients and methods: Plasma samples from 165 patients who stopped first-line antiretroviral therapy containing either zidovudine or stavudine were examined for the presence of drug-resistant genotypes. Subsequent second-line immunological and virological follow-up was performed in 136 patients who switched from zidovudine to stavudine and conversely. Results: Among the 93 patients who stopped first-line therapy including zidovudine and the 72 who stopped first-line therapy including stavudine, genotypic resistance testing was available for 67 (72%) and 54 (75%), respectively. The presence of TAMs was significantly more frequent in the zidovudine than the stavudine group (23.8% versus 5.5; P = 0.006). The short- and long-term immunological and virological responses to second-line therapy were comparable in the zidovudine and stavudine groups, despite different baseline profiles of viral resistance (median increase in CD4 cells/mm(3) at 1 year of therapy, 118 versus 119; viral load <400 copies/mL, 47% versus 47%). Conclusions: These results suggest that TAMs occur in more patients on antiretroviral regimens including zidovudine than on regimens including stavudine. Although the results from observational studies should be interpreted cautiously, these findings may be useful in determining the optimal sequencing of zidovudine and stavudine for the treatment of naive HIV-1-infected patients.
引用
收藏
页码:89 / 94
页数:6
相关论文
共 16 条
[11]   Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy [J].
Pellegrin, I ;
Izopet, J ;
Reynes, J ;
Denayrolles, M ;
Montes, B ;
Pellegrin, JL ;
Massip, P ;
Puel, J ;
Fleury, H ;
Segondy, M .
AIDS, 1999, 13 (13) :1705-1709
[12]   Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine [J].
Picard, V ;
Angelini, E ;
Maillard, A ;
Race, E ;
Clavel, F ;
Chêne, G ;
Ferchal, F ;
Molina, JM .
JOURNAL OF INFECTIOUS DISEASES, 2001, 184 (06) :781-784
[13]   Thymidine analog and multinucleoside resistance mutations are associated with decreased phenotypic susceptibility to stavudine in HIV type 1 isolated from zidovudine-naive patients experiencing viremia on stavudine-containing regimens [J].
Ross, L ;
Scarsella, A ;
Raffanti, S ;
Henry, K ;
Becker, S ;
Fisher, R ;
Liao, QM ;
Hirani, A ;
Graham, N ;
St Clair, M ;
Hernandez, J .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2001, 17 (12) :1107-1115
[14]   Failure of stavudine-lamivudine combination therapy in antiretroviral-naive patients with AZT-like HIV-1 resistance mutations [J].
Sarmati, L ;
Nicastri, E ;
Parisi, SG ;
D'Ettorre, G ;
Narciso, P ;
Mancino, G ;
Gallo, I ;
Abbadessa, V ;
Dalle, NER ;
Traina, C ;
Vullo, V ;
Andreoni, M .
JOURNAL OF MEDICAL VIROLOGY, 2001, 65 (04) :631-636
[15]   Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts [J].
Yazdanpanah, Y ;
Chêne, G ;
Losino, E ;
Goldie, SJ ;
Merchadou, LD ;
Alfandari, S ;
Seage, GR ;
Sullivan, L ;
Marimoutou, C ;
Paltiel, AD ;
Salamon, R ;
Mouton, Y ;
Freedberg, KA .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2001, 30 (04) :864-871
[16]   Antiretroviral treatment for adult HIV infection in 2002 - Updated recommendations of the international AIDS Society-USA panel [J].
Yeni, PG ;
Hammer, SM ;
Carpenter, CCJ ;
Cooper, DA ;
Fischl, MA ;
Gatell, JM ;
Gazzard, BG ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schechter, M ;
Schooley, RT ;
Thompson, MA ;
Vella, S ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (02) :222-235